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     BSTRACT
Alfaxalone is a synthetic neurosteroid anesthetic agent widely used in veterinary medicine, 
with a wide margin of safety and good quality of anesthesia. Also, alfaxalone has rapid biotrans-
formation and a low tendency to accumulate in the tissues after repeated doses, which favors its 
intravenous use as a constant rate infusion. The aim of the study was to assess the isoflurane-
sparing property and the clinical effects on the cardiorespiratory system of alfaxalone used as 
constant rate infusion in goats. Three healthy female goats were included in the study. Each goat 
was anesthetized twice (interval fifteen days) and received the following treatments in a random 
order during maintenance of anesthesia: 1. alfaxalone administered as a constant rate infusion at 
0.05 mg/kg/min (treatment A); 2. NaCl 0.9% solution at an identical infusion rate (treatment B). 
Isoflurane vaporizer settings were adjusted according to a flow-chart. The SpO2 was significantly 
lower during treatment B than during treatment A. Although no significant differences were 
demonstrated for the other variables (heart rate, etc.), a clinical effect was noticed, including 
a modest decrease in the expired isoflurane concentration with treatment A. In conclusion, the 
co-administration of alfaxalone in isoflurane-anesthetized goats seems to result in only minimal 
side effects on cardiorespiratory parameters and may reduce the isoflurane requirements, but 
further studies are needed to confirm these results.
SAMENVATTING
Alfaxalone is een synthetisch neurosteroïde anestheticum dat veel wordt gebruikt in de dierge-
neeskunde en een goede kwaliteit van anesthesie biedt. Het heeft een snelle biotransformatie en accu-
muleert weinig in de weefsels na herhaalde dosering, waardoor het geschikt is als continu infuus voor 
het onderhoud van de anesthesie. Het doel van de studie was om de isofluraansparende eigenschap 
van alfaxalone toegediend als ‘constante snelheid infusie’ voor het onderhoud van de anesthesie bij 
geiten en de klinische effecten ervan op het cardiorespiratoire systeem te beoordelen. Drie gezonde, 
vrouwelijke geiten werden opgenomen in de studie en tweemaal onder anesthesie gebracht (met een 
interval van vijftien dagen). Bij elke anesthesie werd een van de volgende behandelingen toegepast 
(willekeurige volgorde): 1. alfaxalone-infuus aan 0,05 mg/kg/min (behandeling A); 2. 0,9% NaCl-
oplossing aan eenzelfde infusiesnelheid (behandeling B). De instellingen van de isofluraanverdamper 
werden aangepast volgens een stroomdiagram. De SpO2 was significant lager tijdens behandeling B 
dan tijdens behandeling A. Hoewel er geen significante verschillen werden aangetoond in de andere 
variabelen, i. e. hartfrequentie, etc., werd een klinisch effect opgemerkt, waaronder een matige daling 
in de vereiste dosis isofluraan. De toediening van alfaxalone bleek bij geiten onder isofluraananesthesie 
minimale cardiorespiratoire veranderingen te veroorzaken en mogelijk een klinisch isofluraansparend 
effect te hebben. Verder onderzoek is echter nodig om deze resultaten te bevestigen
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INTRODUCTION
The term balanced anesthesia is mostly used for a 
combination of anesthetics, analgesics and adjuvants 
to achieve analgesia, hypnosis, muscle relaxation, 
amnesia, maintenance of normal homeostasis and re-
duction or elimination of autonomic reflexes (Tonner 
2005). By combining different agents and techniques, 
a synergistic effect may be achieved, which helps to 
reduce the likelihood of side effects during the main-
tenance of the anesthesia.
Alfaxalone is a synthetic neuroactive steroid anes-
thetic agent with a wide margin of safety and provides 
good quality of muscle relaxation, calmness during 
induction and an uneventful recovery, with minor 
clinically significant adverse cardiorespiratory effects 
in sheep and goats (Andaluz et al., 2012; Dzikiti et 
al., 2014). Previous studies in dogs (Ferré et al., 2006) 
and cats (Whittem et al., 2008) have demonstrated a 
dose-dependent systemic exposure with a rapid clear-
ance, short terminal elimination half-life and lack of 
accumulation after maintenance with repeated boluses 
(2 and 10 mg/kg for dogs; 5 mg/kg followed by four 
doses of 2 mg/kg in cats). In a recent study by Dehuis-
ser et al. (2019a and 2019b), cardiovascular function 
and pharmacokinetic parameters were shown to be 
stable during continuous administration of alfaxalone 
in dogs (Dehuisser et al., 2019a, 2019b). Therefore, 
all the aforementioned properties favor the use of al-
faxalone as a constant rate infusion (CRI).
In goats, a minimum infusion rate of 0.16 mg/kg/
min is needed to maintain total intravenous anesthesia, 
with minimal cardiorespiratory effects and a smooth 
recovery (Ndawana et al., 2014). Similarly, Moll et 
al., (2013) showed that the same rate infusion of al-
faxalone in unpremedicated sheep maintained clini-
cally acceptable hemodynamic stability, with mild 
respiratory depression. The use in combination with 
co-adjuvants midazolam or fentanyl has shown an 
eight-fold reduction for the alfaxalone constant rate 
infusion in goats (Dzikiti et al., 2015; Dzikiti et al., 
2016). Furthermore, in desflurane-anesthetized sheep, 
a low alfaxalone CRI rate (0.07 mg/kg/min) reduces 
the desflurane requirements to maintain a suitable an-
esthetic depth (Granados et al., 2012).
The aim of the present study was to assess the 
clinical effects of a CRI of alfaxalone on the cardio-




The study was approved (EC 2013/76) by the ethi-
cal committee of the Faculties of Veterinary Medicine 
and Bioscience Engineering of Ghent University. A 
prospective, crossover, randomized, blinded pilot 
study was designed.
Three female, adult goats with a weight of 50 ± 13 
kg (mean ± standard deviation) (range 36 – 62), that 
had already been included in a trial on subcutaneous 
implantation of a wireless glucometer, were included 
in the study. The goats were considered healthy on 
the basis of a physical examination. The goats were 
housed indoors and fed with a standard commercial 
diet. The animals were fasted for 12 to 18 hours and 
deprived of water for 8 to12 hours prior to the experi-
ment, in order to reduce the likelihood of complica-
tions associated with recumbency and anesthesia. On 
the morning of the trials, the physical status of the 
goats was re-evaluated.
An intravenous (IV) 14 gauge over-the-needle 
catheter (Optiva 2, Smiths Medical International, UK) 
was placed aseptically into the left jugular vein. Pre-
medication was performed with IV administration of 
midazolam (0.3 mg/kg Dormicum, Roche, Belgium) 
in combination with morphine (0.1 mg/kg Morphine 
HCl; Oterop, Belgium). Following sedation, the goats 
were preoxygenated for three minutes by direct flow 
of 4 L/min of 100% oxygen using a mask. Anesthe-
sia was then induced slowly with IV alfaxalone until 
endotracheal intubation was possible. After intuba-
tion, the goats were placed in lateral recumbency on a 
smooth, flat and padded surface. The head was posi-
tioned so that the salivary secretions and gastric con-
tents, if regurgitated only, could drain from the mouth 
and not wick between the animal’s head and the pad, 
so that contact with the eyes was avoided. A circulat-
ing warm-water heating blanket was used to prevent 
hypothermia. Anesthesia was maintained with isoflu-
rane (Isoflo, Abbott Laboratories, UK) in a mixture of 
oxygen and air (70%) delivered through a rebreathing 
circle system. The animals were allowed to breathe 
spontaneously. Ringer’s lactate solution was adminis-
tered IV at a rate of 5 mLkg/h. 
All goats were anesthetized twice (for SC im-
plantation of the glucometer and the subsequent re-
moval of the device), with a minimum resting peri-
od of fifteen days between the two sessions. During 
anesthesia, one of two treatments was administered. 
The treatments were allocated in a randomized order, 
which was determined by lottery (extracting a code 
from a sealed envelope). Treatment A consisted of the 
administration of alfaxalone (Alfaxan 10 mg/mL, Ve-
toquinol, France) as a constant rate infusion (CRI) at 
0.05 mg/kg/min; treatment B included the administra-
tion of a NaCl 0.9 %-solution (Baxter, Belgium) at an 
identical infusion rate. 
Monitoring included electrocardiography (ECG) 
and heart rate (HR), pulse oximetry (SpO2), blood 
pressure (BP) measurement (invasive method by a 
20-gauge over-the-needle catheter placed in the ma-
jor auricular artery; oscillometric method using a cuff 
placed on the thoracic limb), capnography (ETCO2), 
respiratory rate (fR) and inspiratory and expiratory 
isoflurane concentrations FI´ISO and FE′ISO, respec-
tively (Datex-Ohmeda Monitor, Datex-Ohmeda, Fin-
land). The anesthetic depth (isoflurane setting) was 
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adjusted according to a flow-chart (Figure 1). Recov-
ery was performed on a padded surface in a recovery 
room and the animals were not extubated till the la-
ryngeal reflex returned. Possible adverse events dur-
ing the recovery were recorded.
All the data were collected at predetermined times 
until the end of the surgery by a single observer, who 
was experienced in the clinical methods and scoring 
systems used in this trial, but who was blinded to the 
assigned treatments.
Statistical analysis
Data analysis was performed using commer-
cially available computer software (SPSS Statistics 
22.0, Chicago, IL). The Shapiro Wilk test was used 
to assess the normal distribution of data. Normally 
distributed data were expressed as mean ± standard 
deviation, and non-parametric data were expressed 
as median (range). The overall values for HR, SpO2, 
BP, ETCO2, fR, FI´ISO and FE′ISO were compared 
between treatments by a Mann Whitney U-test. When 
this test revealed significant differences, the Wilcox-
on signed rank test was used to analyze for predeter-
mined timepoints. A value of p < 0.05 was considered 
significant for all statistical tests.
RESULTS
The total mean duration of the procedure with 
either the saline or alfaxalone CRI was 68.3 ± 17.2 
minutes (min). Time 0 (t0) was considered 10 minutes 
before starting the surgery. Although there were no 
significant differences between the groups, the dura-
tion of the procedure was forty minutes in two cases. 
Therefore, statistical analysis was only performed on 
data collected during the first forty minutes of every 
experimental animal.
Moderate differences were found for some vari-
ables, but these were not significant for HR, BP, 
ETCO2, fR, FI´ISO and FE′ISO (Figure 2). Systolic 
(SAP), diastolic (DAP) and mean (MAP) arterial 
blood pressure were initially lower with treatment A, 
but gradually increased towards the end of the trial. 
The HR values were lower in the goats in group A 
(98.1 ± 15.7) than in group B (107.5 ± 13.1), but the 
difference was not significant. The FE′ISO gradually 
decreased over time with treatment A, and although 
the overall value during the observational period was 
lower (0.91 ± 0.26%) than in group B (1.03 ± 0.23%), 
the difference was not significant. 
The only significant difference between the treat-
ments was found for SpO2, which was lower during 
treatment B than during treatment A at t0, t10, t20, t30 
and t40 (p = 0.027, p = 0.027, p = 0.027, p = 0.028 and 
p = 0.027, respectively) (Figure 2).
No adverse events were noticed during the recov-
ery period.
DISCUSSION 
In this present pilot study, the use of a CRI of al-
faxalone at 0.05 mg/kg/min is demonstrated to result 
in minimal cardiorespiratory changes, and even to 
Figure 1. Flow chart used to modify isoflurane settings in isoflurane-anesthetized goats (n =3) combined with an alfaxa-
lone constant rate infusion at 0.05 mg/kg/min.
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Figure 2. Graphical representation (from top left 
to bottom right) of heart rate (HR), pulse oximetry 
(SpO2), systolic (SBP), diastolic (DBP) and mean 
blood pressure (MBP) measurement, capnography 
(ETCO2), respiratory rate (fR), and inspiratory and 
expiratory isoflurane concentrations (FI´ISO and 
FE′ISO, respectively) between alfaxalone (light grey 
and circle dotted line) and saline (dark grey and tri-
angle dotted line) constant rate infusion in isoflurane-
anesthetized goats. Grey star means significant differ-
ences at each time point between both treatments (p 
< 0.05). 
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improve pulse oximetry readings in isoflurane-anes-
thetized goats. Although no significant differences 
were observed for the other variables (most likely due 
to the small sample size), the results suggest that an 
alfaxalone CRI may have some isoflurane-sparing ef-
fects. However, further studies are needed to confirm 
this. 
A constant rate of 0.05 mg/kg/min (or 3 mg/kg/h) 
of alfaxalone was used in the protocol for isoflurane-
anesthetized experimental goats of the present trial. 
In the veterinary literature, a great variability be-
tween species can be found in terms of the infusion 
regimens. In earlier reports, it has been shown that 
alfaxalone administered in CRI at 0.07 and 0.11 mg/
kg/min for total intravenous anesthesia (TIVA) pro-
duces a clinically acceptable anesthetic depth for sur-
gical procedures in dogs (Ambros et al., 2008; Suarez 
et al., 2012). More recent studies have shown car-
diovascular stability and a good plane of anesthesia 
when alfaxalone is continuously administered at 0.15 
mg/kg/min in dogs (Dehuisser et al., 2017, 2019a). 
Schwarz et al., (2014) established a minimum infu-
sion rate (MIR) of 10 mg/kg/h (0.18 mg/kg/min) for 
TIVA with alfaxalone as a sole agent in cats (Schwarz 
et al., 2014). Conversely, a lower infusion rate (3 mg/
kg/h or 0.05 mg/kg/min) has been shown to maintain 
an adequate depth of anesthesia in horses (Goodwin 
et al., 2018). Nevertheless, Ndawana et al., (2014) 
showed that a MIR of 0.16 mg/kg/min (10 mg/kg/h) 
of alfaxalone was feasible to prevent gross movement 
of trunk, head or limbs after supramaximal noxious 
stimuli in goats.
In the present study, the FE′ISO required to main-
tain anesthesia was lower with treatment A, although 
the difference was not significant (p = 0.195). Simi-
larly, in desflurane-anesthetized sheep, infusion of 
alfaxalone at a rate of 0.07 mg/kg/min results in a de-
crease of desflurane requirements to maintain a surgi-
cal depth of anesthesia (Granados et al., 2012). Also, 
co-administration of a fentanyl CRI (10 µg/kg/h) re-
sults in a significant decrease of the alfaxalone infu-
sion rate in dogs (Dehuisser et al., 2017), while com-
binations with medetomidine (3 – 5 µg/kg/h) alone or 
with either butorphanol (30 µg/kg/h) or guaifenesin 
(80 mg/kg/h) have been demonstrated to reduce the 
alfaxalone dose regimen (1.5 – 2 mg/kg/h or 0.025 
– 0.033 mg/kg/min) for TIVA in horses (Goodwin et 
al., 2013; Ohmura et al., 2016; Aoki et al., 2017). In 
goats, a significant reduction of the alfaxalone CRI 
down to 0.02 mg/kg/min has been observed after a 
combination with either midazolam (0.1 – 0.9 mg/
kg/h) or fentanyl (5 – 30 µg/kg/h) (Dzikiti et al., 2015; 
Dzikiti et al., 2016). The results of the present report 
suggest that an alfaxalone CRI at 0.05 mg/kg/min, 
possibly in combination with other drugs, may reduce 
the required dose of inhalant anesthetics delivered to 
the patient, which warrants further research.
Although cardiovascular parameters were with-
in normal ranges throughout anesthesia, BP values 
were lower in the initial phase of the procedure dur-
ing treatment A, with minimal or no initial changes 
in the HR. Dose-dependent decrease in systolic arte-
rial pressure and systemic vascular resistance, due to 
a vasodilatory effect, have previously been reported 
after clinical and supraclinical induction doses of al-
faxalone in dogs and cats (Muir et al., 2008; Muir et 
al.,, 2009). Furthermore, alfaxalone administered in 
either boluses or CRI for TIVA may cause hypoten-
sion in cats (Beths et al., 2014; Schwarz et al., 2014). 
However, either no side effects or minimal changes 
in the hemodynamic parameters have been shown 
after alfaxalone CRI in dogs (Ambros et al., 2008) 
and horses (Goodwin et al., 2018). While balanced 
cardiovascular parameters have been recorded dur-
ing TIVA with alfaxalone CRI in goats (Ndawana et 
al., 2014), a delayed hypotensive state (between 45 
and 75 minutes after the start of the alfaxalone CRI) 
has been demonstrated in desflurane-anesthetized 
sheep (Granados et al., 2012). The results of the pres-
ent study show that HR and BP were not affected by 
co-administration of 0.05 mg/kg/h alfaxalone CRI in 
isoflurane-anesthetized goats.
The SpO2 readings were significantly higher dur-
ing the co-administration of alfaxalone CRI than in 
the saline group. This may be an incidental finding, 
or may indicate better pulmonary gas exchange and/
or lung perfusion with treatment A, resulting in im-
proved arterial oxygenation. Alternatively, the authors 
hypothesize that the alfaxalone CRI could have im-
proved the peripheral blood flow either by the afore-
mentioned vasodilatory effect, or due to an increase 
in the cardiac index after improvement of the myocar-
dial contractility, as previously reported in desflurane-
anesthetized sheep (Granados et al., 2012). However, 
further studies are needed including blood gas analy-
ses and invasive cardiovascular monitoring before fi-
nal conclusions can be drawn.
The most important limitation of this research is 
the very small sample size. This study should there-
fore be regarded as a true pilot study. Based on the dif-
ference found in this study for FE′ISO, a sample size 
calculation was performed (www.powerandsample-
size.com), and it was shown that to achieve a power of 
80%, with p < 0.05, thirty six goats are needed to find 
significant differences in FE′ISO  between the control 
group and the alfaxalone CRI group.
In conclusion, the co-administration of alfaxa-
lone at an infusion rate of 0.05 mg/kg/h may have 
a sparing effect in isoflurane requirements in goats. 
The cardiorespiratory function was well-maintained 
and no abnormalities were observed during either the 
maintenance with alfaxalone CRI or during recovery. 
Further investigations on the use of a constant rate 
infusion of alfaxalone as co-adjuvant in the mainte-
nance of anesthesia in goats have to be performed. It 
should however be emphasized that alfaxalone can be 
used in goats under experimental conditions, but not 
in food-producing species as it is not included in EU 
Regulation 37/2010. 
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